Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to $47.4 million.

  • Camp4 Therapeutics' Cash from Financing Activities rose 12375.65% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.4 million, marking a year-over-year increase of 8327.41%. This contributed to the annual value of $71.7 million for FY2024, which is 23707.97% up from last year.
  • Camp4 Therapeutics' Cash from Financing Activities amounted to $47.4 million in Q3 2025, which was up 65,711.11% from $72,000 recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' Cash from Financing Activities registered a high of $73.1 million during Q4 2024, and its lowest value of -$812,000 during Q2 2024.
  • In the last 3 years, Camp4 Therapeutics' Cash from Financing Activities had a median value of -$107,000 in 2023 and averaged $14.9 million.
  • Data for Camp4 Therapeutics' Cash from Financing Activities shows a peak YoY spiked of 116,071.43% (in 2024) over the last 5 years.
  • Over the past 3 years, Camp4 Therapeutics' Cash from Financing Activities (Quarterly) stood at -$63,000 in 2023, then skyrocketed by 116,071.43% to $73.1 million in 2024, then skyrocketed by 12,375.65% to $47.4 million in 2025.
  • Its Cash from Financing Activities stands at $47.4 million for Q3 2025, versus $72,000 for Q2 2025 and -$151,000 for Q1 2025.